2023
Maternal diabetes in youth-onset type 2 diabetes is associated with progressive dysglycemia and risk of complications
RD S, SD C, L E, ME G, J K, MM K, R F, B T, JB T, M V, E I. Maternal diabetes in youth-onset type 2 diabetes is associated with progressive dysglycemia and risk of complications. 2023 DOI: 10.1530/ey.20.10.7.Peer-Reviewed Original Research
2022
When insulin isn’t enough: targeting glucagon in type 1 diabetes
Van Name M, Sherr J. When insulin isn’t enough: targeting glucagon in type 1 diabetes. Nature Medicine 2022, 28: 2007-2008. PMID: 36192555, DOI: 10.1038/s41591-022-02019-3.Commentaries, Editorials and LettersYouth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2021
Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observational real‐world cohort study
Dovc K, Van Name M, Bizjan B, Rusak E, Piona C, Yesiltepe‐Mutlu G, Mentink R, Frontino G, Macedoni M, Ferreira SH, Serra‐Caetano J, Galhardo J, Pelicand J, Silvestri F, Sherr J, Chobot A, Biester T, Group F. Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observational real‐world cohort study. Diabetes Obesity And Metabolism 2021, 24: 564-569. PMID: 34820985, PMCID: PMC9306649, DOI: 10.1111/dom.14607.Peer-Reviewed Original Research
2020
A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes.
Laffel L, Harrington K, Hanono A, Naik N, Ambler-Osborn L, Schultz A, DiMeglio L, Woerne S, Jolivette H, Ismail H, Tebbe M, Newman A, Legge M, Tamborlane W, Van Name M, Weyman K, Finnegan J, Steffen A, Zgorski M, DeSalvo D, Hilliard M, DeLaO K, Xie C, Levy W, Wadwa R, Forlenza G, Majidi S, Alonso G, Weber I, Clay M, Simmons E, Nathan B, Sunni M, Sweet J, Pappenfus B, Kogler A, Ludwig M, Nelson B, Street A, Weingartner D, Albanese-O’Neill A, Haller M, Adams J, Cintron M, Thomas N, Kelley J, Simmons J, William G, Brendle F, Goland R, Williams K, Gandica R, Pollak S, Casciano E, Robinson E, Willi S, Minnock P, Olivos D, Carchidi C, Grant B, Wong J, Adi S, Corathers S, Sheanon N, Fox C, Weis T, MacLeish S, Wood J, Casey T, Campbell W, McGuigan P, Wintergerst K, Watson S, Kingery S, Pierce G, Ruch H, Rayborn L, Rodriguez-Luna M, Deuser A. A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes. Diabetes Care 2020, 44: 464-472. PMID: 33334807, PMCID: PMC9162100, DOI: 10.2337/dc20-1060.Peer-Reviewed Original ResearchConceptsType 1 diabetesBlood glucose monitoringContinuous glucose monitoringFamily behavioral interventionsGlucose monitoringFingerstick blood glucose monitoringBehavioral interventionsSevere hypoglycemic eventsDays/weekYears of ageFear of hypoglycemiaYoung childrenTreatment group comparisonsChildren ages 2Very Young ChildrenHypoglycemic eventsCGM groupDiabetes burdenClinical trialsGlycemic outcomesGlucose levelsPrimary analysisDiabetesBGM groupPercent time‘I’m essentially his pancreas’: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes
PV C, KR H, AL W, KM M, ME H, M V, DJ D, WV T, BJ A, LA D, LM L. ‘I’m essentially his pancreas’: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. 2020 DOI: 10.1530/ey.17.10.10.Peer-Reviewed Original ResearchHealth Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study
Weinstock R, Braffett B, Songer T, Herman W, Kuo S, Gubitosi-Klug R, Laffel L, McKay S, Siska M, Van Name M, Zeitler P. Health Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study. Diabetes Care 2020, 43: 2469-2477. PMID: 32778555, PMCID: PMC7510035, DOI: 10.2337/dc20-0760.Peer-Reviewed Original ResearchConceptsType 2 diabetesHealth care coverageCare coverageGlycemic controlYoung adultsYouth-onset type 2 diabetesCommunity careYouth-Onset Type 2Medicaid expansionCommercial coverageCommunity diabetes careGovernment coverageDiabetes careDiabetes visitsTreatment optionsMore young adultsNew therapiesType 2DiabetesTODAY cohortCentral laboratoryVulnerable populationsCareCommercial plansHbATransforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model
Van Name M, Klingensmith G, Nelson B, Wintergerst K, Mitchell J, Norris K, Tamborlane W, Clements M, Hannon T, Shoemaker A, Wood J, Gal R. Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model. Diabetes Technology & Therapeutics 2020, 22: 330-336. PMID: 31859529, PMCID: PMC7869879, DOI: 10.1089/dia.2019.0448.Peer-Reviewed Original ResearchConceptsPediatric Diabetes ConsortiumType 2 diabetesClinical centersCoordinating CenterPediatric treatment centerPediatric type 1 diabetesPhase 3 trialType 2 Diabetes StudyType 1 diabetesPediatric Type 2Diabetes-related studiesTreatment of youthPivotal trialsRandomized subjectsDiabetes StudyStudy protocolClinical trialsContract research organizationsConsortium modelTreatment centersType 2DiabetesNew drugsTrialsEnrollment strategiesSources and Valence of Information Impacting Parents' Decisions to Use Diabetes Technologies in Young Children <8 Years Old with Type 1 Diabetes
Commissariat P, Whitehouse A, Hilliard M, Miller KM, Harrington KR, Levy W, DeSalvo DJ, Van Name M, Anderson B, Tamborlane W, DiMeglio LA, Laffel L. Sources and Valence of Information Impacting Parents' Decisions to Use Diabetes Technologies in Young Children <8 Years Old with Type 1 Diabetes. Diabetes Technology & Therapeutics 2020, 22: 697-700. PMID: 32077755, PMCID: PMC7718841, DOI: 10.1089/dia.2019.0497.Peer-Reviewed Original ResearchConceptsType 1 diabetesDiabetes technologyCare providersYoung childrenDiabetes care providersHealth care providersCaregivers of childrenDiabetes technology useSubset of parentsDiabetesCare optionsType 1Most parentsUnderwent content analysisChildrenParents' decisionsProvidersSemi-structured interviewsParentsYears
2019
“I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes
Commissariat PV, Harrington KR, Whitehouse AL, Miller KM, Hilliard ME, Van Name M, DeSalvo DJ, Tamborlane WV, Anderson BJ, DiMeglio LA, Laffel LM. “I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. Pediatric Diabetes 2019, 21: 377-383. PMID: 31808586, PMCID: PMC7830825, DOI: 10.1111/pedi.12956.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlycemic controlDiabetes burdenSecondary caregiversEmotional burdenChildren's glycemic controlYoung childrenCare of childrenAge 5.2Parents' perceptionsCaregivers' knowledgeClinical centersSemi-structured qualitative interviewsDiabetesDiabetes educationParental burdenHealthcare providersAge groupsInsulin pumpParents' burdenT1DChildren's qualityChild's diabetesParents' knowledgeParents' confidencePharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugsImpact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2DegludecChapter 12 Medications for the Treatment of Type II Diabetes
Van Name M. Chapter 12 Medications for the Treatment of Type II Diabetes. 2019, 101-106. DOI: 10.1016/b978-0-323-55138-0.00012-7.Chapters
2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollmentThe present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent use
2017
Management and Family Burdens Endorsed by Parents of Youth <7 Years Old With Type 1 Diabetes
Harrington KR, Boyle CT, Miller KM, Hilliard ME, Anderson BJ, Van Name M, DiMeglio LA, Laffel LM. Management and Family Burdens Endorsed by Parents of Youth <7 Years Old With Type 1 Diabetes. Journal Of Diabetes Science And Technology 2017, 11: 980-987. PMID: 28770627, PMCID: PMC5951003, DOI: 10.1177/1932296817721938.Peer-Reviewed Original ResearchConceptsType 1 diabetesDiabetes managementT1D Exchange Clinic RegistryDuration of diabetesMean hemoglobin A1cFamily impact scoresLow blood sugarQuality of sleepYoung childrenMedical record informationClinical characteristicsHemoglobin A1cSerious complicationsBlood sugarClinic registryMean ageFamily burdenSubstantial burdenParental burdenDiabetesAge groupsInsulin pumpType 1Parents of youthChildren's diabetes management
2013
Reliable Assessment of Insulin Resistance in Children
Van Name M, Caprio S. Reliable Assessment of Insulin Resistance in Children. Current Cardiovascular Risk Reports 2013, 7: 256-260. PMID: 36845034, PMCID: PMC9957558, DOI: 10.1007/s12170-013-0315-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements